How does tigecycline affect the liver and raise liver enzymes?
Tigecycline can cause liver test abnormalities by triggering liver cell injury (a hepatocellular pattern) or by impairing bile flow (a cholestatic pattern). Clinically, this shows up as increases in enzymes such as ALT and AST, sometimes along with rises in alkaline phosphatase and bilirubin [1][2].
What mechanisms are thought to explain elevated ALT/AST with tigecycline?
The exact mechanism is not always clear in individual patients, but liver enzyme elevations with tigecycline are generally attributed to drug-induced liver injury (DILI). DILI can occur through:
- Direct toxic effects on hepatocytes that lead to cell stress or injury, raising ALT/AST [1][2]
- Immune-mediated injury in some cases, where the body’s response contributes to hepatocyte damage (a known DILI pathway for many antibiotics) [1][2]
- Effects on bile transport that can lead to cholestasis, which can raise alkaline phosphatase and sometimes bilirubin [1][2]
What lab patterns might patients see?
Depending on the injury type, tigecycline-associated liver enzyme elevations may look like:
- Hepatocellular: ALT/AST rise more than alkaline phosphatase [1][2]
- Cholestatic: alkaline phosphatase (and sometimes bilirubin) rise more prominently [1][2]
- Mixed: both transaminases and cholestatic markers increase [1][2]
What situations make tigecycline-related enzyme elevations more likely?
Risk can be higher when patients have factors that predispose to DILI or liver stress, including:
- Pre-existing liver disease or impaired hepatic function [1]
- Serious underlying illness and systemic infection, which can independently affect liver tests
- Concomitant medications that also affect the liver, increasing the chance of additive toxicity (common in hospitalized patients) [1]
- Prolonged or higher-dose exposure, which increases the chance of adverse drug reactions [1][2]
When do liver enzymes usually rise, and what should clinicians watch for?
Liver test abnormalities can appear after starting therapy and may be detected during routine monitoring. Clinicians typically watch for:
- Rising ALT/AST, alkaline phosphatase, and bilirubin trends
- Signs of clinically significant DILI, such as jaundice or symptoms (fatigue, nausea, right upper abdominal discomfort)
- Worsening trends after drug exposure begins, which may prompt stopping the drug depending on severity [1][2]
What happens if liver enzymes climb while on tigecycline?
If liver enzymes increase, the next step generally depends on how high they are and whether bilirubin or symptoms accompany the rise. In many DILI approaches, clinicians consider holding or discontinuing the suspected drug and evaluating other causes (viral hepatitis, biliary obstruction, sepsis-related changes, other hepatotoxic drugs) [1][2]. The prescribing information and clinical guidance typically emphasize dose/therapy reassessment when significant abnormalities occur [1].
Could tigecycline cause jaundice, not just enzyme elevations?
Yes. Tigecycline can be associated with clinically apparent liver injury that includes bilirubin elevations and jaundice in some cases, not only isolated lab abnormalities [1][2].
---
Sources
[1] https://www.drugs.com/tigecycline.html
[2] https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=tigecycline%20package%20insert